Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.78 |
| ▸ | CHRM3 | P20309 | 17/20 | 0.58 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.58 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL942153 | 0.96 | CHRM2 (0.81) | CHRM2CHRM3ADRB2SLC2A1 | |
| SCHEMBL644736 | 0.93 | CHRM2 (0.74) | CHRM2CHRM3ADRB2 | |
| SCHEMBL1302816 | 0.92 | CHRM2 (0.85) | CHRM2CHRM3ADRB2SLC2A1 | |
| SCHEMBL646748 | 0.91 | CHRM2 (0.72) | CHRM2CHRM3ADRB2 | |
| SCHEMBL942556 | 0.91 | CHRM2 (0.81) | CHRM2CHRM3ADRB2SLC2A1 | |
| SCHEMBL1303125 | 0.90 | CHRM2 (0.80) | CHRM2CHRM3ADRB2SLC2A1 | |
| SCHEMBL1303025 | 0.90 | CHRM2 (0.84) | CHRM2CHRM3ADRB2SLC2A1 | |
| SCHEMBL31221643 | 0.89 | CHRM2 (0.88) | CHRM2CHRM3ADRB2SLC2A1 | |
| SCHEMBL942211 | 0.89 | CHRM2 (0.88) | CHRM2CHRM3ADRB2SLC2A1 | |
| SCHEMBL3763194 | 0.89 | CHRM2 (0.73) | CHRM2CHRM3ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1856112-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2007-11-21 | — | — | EP | claimed |
| WO-2006099032-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2006-09-21 | — | — | WO | claimed |
| US-20060205775-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2006-09-14 | — | — | US | claimed |
| US-8501776-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20110071190-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2011-03-24 | — | — | US | disclosed |
| US-7868175-B2 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2011-01-11 | — | — | US | disclosed |
| US-20100041701-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-7629336-B2 | Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-[2-((4-[4-(2-hydroxyethylcarbamoyl)piperidin-1-ylmethyl]benzoyl)methylamino)ethyl]piperidin-4-yl ester | THERAVANCE, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20060205775-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | THERAVANCE, INC. | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205775-A1 | Biphenyl compounds useful as muscarinic receptor antagonists | CHRM2, CHRM3, CHRM1 | CHRM2 1/4885CHRM3 2/4885ADRB2 22/4885 |
| US-20100041701-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM3, CHRM1 | CHRM2 1/4885CHRM3 2/4885ADRB2 22/4885 |
| US-20110071190-A1 | BIPHENYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | CHRM2, CHRM3, CHRM1 | CHRM2 1/4885CHRM3 2/4885ADRB2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.